A bio that tries to license its drug in this market is in the same quagmire that the car dealers are stuck in. There are lots of cash starved sellers and only a few big pharmas who are demanding discounted prices for any deal made. Allon has chosen to wait it out and hope the climate improves for small bios. They say they have enough cash to reach 2011. Allon should have the schizo cognition P2 results in 2nd qtr which would be notable if positive. They also plan to start FTD trials which may align well with their drug Al-108 because it has shown the ability to reduce the tau related pathology that usually shows up in these FTD diseases. The Investor's village board has a little more life to it than this site so you might try it.